AZN Overview
Upcoming Projects (AZN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AZN)
-
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 24, 2024 at 04:56 PM EDT -
A look at the data presented at ESMO for ovarian cancer treatments including the Phase 2 PICCOLO trial of Elahere in PSOC.
Tickers: ABBV, AZN, GMAB, 600276.XSHG
Executed On: Oct 22, 2024 at 09:30 AM EDT -
Discussing the AMPLIFY Phase III trial of Calquence plus venetoclax as a first line treatment for chronic lymphocytic leukemia
Tickers: AZN, ABBV, RHHBY
Executed On: Aug 29, 2024 at 12:00 PM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic July 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Aug 01, 2024 at 10:42 AM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 18, 2024 at 03:17 PM EDT -
A look at AstraZeneca's PARP1 inhibitor, saruparib, in solid tumors and the results from the phase 1/2a PETRA study presented at the 2024 AACR Annual Meeting.
Ticker: AZN
Executed On: Apr 18, 2024 at 02:00 PM EDT -
Discussing the potential of WAINUA (eplontersen) as an FDA approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy.
Tickers: AZN, IONS
Executed On: Mar 14, 2024 at 05:45 PM EDT -
Understanding the latest R&D advances and clinical development trends in obesity management
Tickers: RHHBY, AMGN, AZN
Executed On: Feb 12, 2024 at 03:00 PM EST -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 22, 2024 at 01:24 PM EST -
Discussing Icosavax's Interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults
Tickers: ICVX, AZN
Executed On: Jan 08, 2024 at 05:30 PM EST -
Quarterly Survey: Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 26, 2023 at 04:59 PM EDT -
Discussing data from the TROPION-Breast01 phase 3 clinical trial of Datopotamab deruxtecan in breast cancer
Tickers: AZN, DSNKY
Executed On: Oct 05, 2023 at 11:00 AM EDT -
Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with a cardiologist
Tickers: NVO, LLY, AZN
Executed On: Aug 22, 2023 at 02:15 PM EDT -
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jul 25, 2023 at 05:46 PM EDT -
Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Allergist
Tickers: SNY, AZN
Executed On: Jul 19, 2023 at 06:30 PM EDT -
Digging into the results from the P3 ALPHA trial of AstraZeneca's danicopan (ALXN2040) in patients with paroxysmal nocturnal hemoglobinuria who experience extravascular hemolysis
Ticker: AZN
Executed On: Jul 11, 2023 at 05:00 PM EDT -
A Second Opinion: Discussing AstraZeneca and Daiichi Sankyo’s DESTINY trial data presented at ASCO 2023 on Enhertu in patients with HER2 advanced solid tumors
Tickers: AZN, DSKYF
Executed On: Jun 15, 2023 at 04:00 PM EDT -
Discussing AstraZeneca and Daiichi Sankyo’s DESTINY trial data presented at ASCO 2023 on Enhertu in patients with HER2 advanced solid tumors
Tickers: AZN, DSKYF
Executed On: Jun 15, 2023 at 03:00 PM EDT -
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy with a neurologist.
Tickers: AZN, IONS
Executed On: May 31, 2023 at 04:00 PM EDT -
Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023
Tickers: LLY, NVO, AZN
Executed On: Apr 12, 2023 at 02:43 PM EDT -
A look at the recent FDA approval of AstraZeneca's Airsupra (albuterol/budesonide) the first and only rescue medication to reduce risk of asthma exacerbations in adults.
Ticker: AZN
Executed On: Jan 31, 2023 at 12:30 PM EST -
Discussing the potential of PARP-inhibitor, Lynparza (olaparib), in combination with abiraterone for patients with mCRPC
Tickers: AZN, JNJ, SUNPHARMA.XBOM
Executed On: Nov 01, 2022 at 11:00 AM EDT -
Discussing the approval of Enhertu as the first HER2-directed therapy in patients with HER2-low metastatic breast cancer
Ticker: AZN
Executed On: Aug 12, 2022 at 04:00 PM EDT
Expired Projects (AZN)
-
Discussing Surface Oncology’s CD39 and CD73 Pipeline in advanced solid tumors
Tickers: SURF, AZN
Execute By: Oct 31, 2021 -
FAERS database request for Veltassa
Tickers: RLYP, AZN
Execute By: Jun 03, 2016 -
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Upcoming & Overdue Catalysts (AZN)
-
PEARL trial from AstraZeneca (AZN), which will test durvalumab versus the current standard of care in treatment of breast cancer, to report data 1H 2022
Ticker: AZN
Future Window: Jan 01, 2022 - Jun 30, 2022
Overdue
Occurred Catalysts (AZN)
-
Efficacy data of Astra-Oxford COVID-19 vaccine (AZD1222) released: ranging from 62% to 90% depending on dosage
Ticker: AZN
Occurred on: Nov 23, 2020 -
Phases 1b-3a ADJUVANT trial by AstraZeneca (AZN), which tests durvalumab for treatment of lung cancer, set for 2020 data readout
Ticker: AZN
Occurred on: Sep 18, 2020 -
AstraZeneca and Astellas working with FibroGen in studies treating CKD anemia, with NDA expected in 2018
Tickers: FGEN, AZN, ALPMY
Occurred on: Oct 01, 2018 -
Top-Line data from AstraZeneca's (AZN) Phase 3 ALPS of Roxadustat for Anemia Due to Chronic Renal Failure expected Q2 2018
Ticker: AZN
Occurred on: Sep 20, 2018 -
Phase 3 IMpassion 130 data of AstraZeneca's (AZN) Tecentriq (atezolizumab) In breast cancer expected Q2 2018
Ticker: AZN
Occurred on: Jul 02, 2018 -
AstraZeneca's (AZN) Imfinzi Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer Interim Analysis Released
Ticker: AZN
Occurred on: May 25, 2018 -
FDA approves AstraZeneca's(AZN) Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer
Ticker: AZN
Occurred on: Apr 18, 2018 -
Results presented from a new sub-analysis of AstraZeneca's(AZN) Phase III PEGASUS-TIMI 54 trial of Brilinta (ticagrelor)
Ticker: AZN
Occurred on: Feb 07, 2018 -
AstraZeneca's(AZN) Lynparza(olaparib) in metastatic breast cancer PDUFA date is set for the first quarter of 2018
Ticker: AZN
Occurred on: Jan 12, 2018 -
FDA approves AstraZeneca's(AZN) once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
Ticker: AZN
Occurred on: Oct 23, 2017 -
AstraZeneca Phase 3 PACIFIC trial—evaluating durvalumab in efficacy for lung cancer—set for data readout in the second half of 2017
Ticker: AZN
Occurred on: Sep 08, 2017 -
Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
Ticker: AZN
Occurred on: Aug 28, 2017 -
FDA set for Q3 2017 action date on AstraZeneca (AZN)'s Lynparza, or olaparib, for relapsed ovarian cancer
Ticker: AZN
Occurred on: Aug 17, 2017 -
Insmed (INSM) Expects to Begin Phase 2 Dose-Ranging Study in 2017 Evaluating AstraZeneca's (AZN) AZD7986 in Non-Cystic Fibrosis Bronchiectasis
Tickers: INSM, AZN
Occurred on: Jul 17, 2017 -
AstraZeneca (AZN) earns full FDA approval for Tagrisso, a treatment for lung cancer
Ticker: AZN
Occurred on: Mar 31, 2017 -
AstraZeneca (AZN) Tagrisso, a treatment for lung cancer, obtains full approval from Chinese FDA
Ticker: AZN
Occurred on: Mar 27, 2017 -
AstraZeneca (AZN) announces receipt of FDA CRL regarding its high potassium drug ZS-9
Ticker: AZN
Occurred on: Mar 17, 2017 -
AstraZeneca's Lynparza (olaparib) phase 3 SOLO-2 trial shows survival benefit in BRCA-Mutated Ovarian Cancer
Ticker: AZN
Occurred on: Mar 14, 2017 -
Valeant's (VRX) Siliq Approved by FDA for Adults with Moderate-to-Severe Plaque Psoriasis
Tickers: VRX, AZN
Occurred on: Feb 16, 2017 -
FDA Lifts Partial Clinical Hold on AstraZeneca's (AZN) Studies of Durvalumab
Ticker: AZN
Occurred on: Nov 22, 2016 -
AstraZeneca's (AZN) Phase 3 KESTREL and EAGLE Clinical Trials for Durvalumab in Head and Neck Cancer Suspended by FDA
Ticker: AZN
Occurred on: Oct 27, 2016 -
AstraZeneca (AZN) Announces Phase 3 SOLO-2 Results Assessing Lynparza in Treatment-Resistant Ovarian Cancer
Ticker: AZN
Occurred on: Oct 26, 2016 -
AstraZeneca to Conduct Phase 2a Clinical Study of AZD1419 in 2016
Ticker: AZN
Occurred on: Oct 20, 2016 -
Resubmitted New Drug Application for AstraZeneca's (AZN) ZS-9 in Hyperkalemia Accepted for Review by FDA
Ticker: AZN
Occurred on: Oct 18, 2016 -
AstraZeneca (AZN) Announces Phase 3 Results for Bydureon + Farxiga in Treatment of Type 2 Diabetes
Ticker: AZN
Occurred on: Sep 16, 2016 -
Benralizumab phase III trials show positive results in severe asthma
Ticker: AZN
Occurred on: Sep 05, 2016 -
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Tickers: AZN, LLY
Occurred on: Aug 22, 2016 -
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients
Tickers: AZN, ARRY
Occurred on: Aug 09, 2016 -
AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of Type 2 diabetes
Ticker: AZN
Occurred on: Jul 19, 2016 -
New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Ticker: AZN
Occurred on: Jun 28, 2016 -
FDA rejects AstraZeneca's ZS-9 NDA -
Tickers: AZN, RLYP
Occurred on: May 27, 2016 -
AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer
Ticker: AZN
Occurred on: May 27, 2016 -
ZS-9 PDUFA date for Hyperkalemia is May 26th, 2016
Tickers: AZN, RLYP, ZSPH
Occurred on: May 27, 2016 -
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
Ticker: AZN
Occurred on: May 12, 2016 -
Relypsa (RLYP) to Present New Analyses on Various Veltassa Trials in Hyperkalemia at National Kidney Foundation 2016 Spring Meeting
Tickers: RLYP, AZN
Occurred on: Apr 28, 2016 -
Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease
Tickers: LLY, AZN
Occurred on: Apr 08, 2016 -
FDA Approves New Indication for FASLODEX (fulvestrant)
Ticker: AZN
Occurred on: Mar 02, 2016 -
AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma
Ticker: AZN
Occurred on: Feb 29, 2016 -
Dynavax and AstraZeneca Ammend their Agreement for Asthma Drug Candidate
Tickers: DVAX, AZN
Occurred on: Jan 19, 2016 -
ZURAMPIC (lesinurad) approved by US FDA for patients with gout
Ticker: AZN
Occurred on: Dec 22, 2015 -
AstraZeneca completes acquisition of ZS Pharma
Tickers: AZN, ZSPH
Occurred on: Dec 17, 2015 -
CymaBay (CBAY) to Present Two Phase 2 Studies of Arhalofenate for Gout Patients at the American College of Rheumatology Annual Meeting
Tickers: CBAY, CELG, AZN, REGN
Occurred on: Nov 07, 2015 -
Immune Design's (IMDZ) MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2
Tickers: IMDZ, AZN
Occurred on: Oct 29, 2015
Strategic Initiatives (AZN)
-
AstraZeneca (AZN) receives US clearance of proposed acquisition of Alexion (ALXN)
Tickers: AZN, ALXN
Announcement Date: Apr 16, 2021 -
AstraZeneca (AZN) to acquire Alexion (ALXN), building its rare disease portfolio
Tickers: AZN, ALXN
Announcement Date: Dec 12, 2020 -
Transgene (TRGNF) enters into a research, option and license deal with AstraZeneca (AZN) in oncolytic virus immunotherapies
Tickers: TRGNF, AZN
Announcement Date: May 02, 2019 -
AstraZeneca (AZN) strikes collaboration worth $6.9B to sell and develop Daiichi Sankyo's (DSNKY) HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan
Tickers: AZN, DSNKY
Announcement Date: Mar 29, 2019 -
AstraZeneca (AZN) and Allergan (AGN) Complete Licensing Agreement for MEDI2070 Antibody Candidate in Mid-Stage Development for Crohn's Disease and Ulcerative Colitis
Tickers: AGN, AZN
Announcement Date: Nov 17, 2016 -
Insmed (INSM) and AstraZeneca (AZN) Announce Worldwide License Agreement Giving INSM Global Exclusive Rights to Develop AZD7986 in Non-Cystic Fibrosis Bronchiectasis
Tickers: INSM, AZN
Announcement Date: Oct 05, 2016 -
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Tickers: PFE, AZN
Announcement Date: Aug 24, 2016 -
AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
Ticker: AZN
Announcement Date: Feb 29, 2016 -
AstraZeneca and Incyte announce new lung cancer clinical trial collaboration
Tickers: AZN, INCY
Announcement Date: Jan 11, 2016 -
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics
Tickers: AZN, MXK:GMODERNA
Announcement Date: Jan 11, 2016
